Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Watch
Primary summary from verified readiness
- Confidence
- 76% · stale
- Computed at
- 2026-09-22T23:27:14.984527+00:00
- Claimed
- 45
- Reported
- 45
- Verified
- 42
- Gap
- +3
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-09-22
Track; not yet
- Why
- Being clinical-stage (oral small molecule, dosed in 2025) and well-capitalized at a $1.8B valuation puts RTR242 ahead of the reprogramming candidates on maturity, but the core autophagy-aging hypothesis remains unvalidated in humans and disclosure is limited
- Next
- Watch for the RTR242 Phase 1 safety/biomarker readout and the additional 2026/2027 first-in-human milestones; reassess once an autophagy-engagement biomarker translates to a clinical signal
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 2
- Tier 2
- 3
- Tier 3
- 1
- Supports
- 3
- Contradicts
- 1
- Context
- 2
- Latest observed
- 2026-05-23
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 2
- 2026-07-19 Reading moved from watch to watch.
- 2026-09-22 Reading moved from watch to watch.